Effect of coagulation factors on discrepancies in International Normalized Ratio results between instruments

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 9, 2012, Pages 1611-1620

  Sølvik, Una Ørvim ^a   Røraas, Thomas Helge ^b   Petersen, Per Hyltoft ^b   Stavelin, Anne Vegard ^a,b   Monsen, Grete ^b   Sandberg, Sverre ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Haraldsplass Deaconess University College Bergen   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Between subject variation; International Normalized Ratio (INR); Method comparison; Nested analysis of variance model (ANOVA); Point of care; Within subject variation

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PROTHROMBIN; WARFARIN;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OUTPATIENT; PLASMA; PRIORITY JOURNAL;

EID: 84867769942     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0820     Document Type: Article

References (36)

1. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
3. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY). Circulation 2011;123:2363-72.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
5. Plesch W, Wolf T, Breitenbeck N, Dikkeschei LD, Cervero A, Perez PL, et al. Results of the performance verification of the CoaguChek XS system. Thromb Res 2008;123:381-9.
6. McBane RD II, Felty CL, Hartgers ML, Chaudhry R, Beyer LK, Santrach PJ. Importance of device evaluation for point-of-care prothrombin time international normalized ratio testing programs. Mayo Clin Proc 2005;80:181-6.
7. Rigelsky J, Choe H, Curtis D, Brosnan M, Mitrovich S, Streetman D. Accuracy of the avosure PT pro system compared with a hospital laboratory standard. Ann Pharmacother 2002;36:380-5.
8. Karon BS, McBane RD, Chaudhry R, Beyer LK, Santrach PJ. Accuracy of capillary whole blood international normalized ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 point-ofcare analyzers. Am J Clin Pathol 2008;130:88-92.
9. Christensen TD, Larsen TB, Jensen C, Maegaard M, Sorensen B. International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. Thromb Haemost 2009;101:563-9.
10. Donaldson M, Sullivan J, Norbeck A. Comparison of international normalized ratios provided by two point-of-care devices and laboratory-based venipuncture in a pharmacist-managed anticoagulation clinic. Am J Health Syst Pharm 2010;67:1616-22.
11. Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003;33:43-51.
12. Horsti J, Uppa H, Vilpo JA. Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. Clin Chem 2005;51:553-60.
13. Tripodi A, Chantarangkul V, Akkawat B, Clerici M, Mannucci PM. A partial factor V deficiency in anticoagulated lyophilized plasmas has been identified as a cause of the international normalized ratio discrepancy in the external quality assessment scheme. Thromb Res 1995;78:283-92.
14. Horsti J. Agreement of Owren and Quick prothrombin times: effects of citrate and calcium concentrations and international sensitivity index correction. Clin Chem 2001;47:940-4.
15. van den Besselaar AM, Witteveen E, Meeuwisse-Braun J, van der Meer FJ. The influence of exogenous magnesium chloride on the apparent INR determined with human, rabbit, and bovine thromboplastin reagents. Thromb Haemost 2003;89:43-7.
16. van den Besselaar AM, Witteveen E, van der Meer FJ. Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma. Thromb Haemost 2008;100:1181-4.
17. Testa S, Morstabilini G, Fattorini A, Galli L, Denti N, D'Angelo A. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica 2002;87:1265-73.
18. Christensen TD, Jensen C, Larsen TB, Christiansen K, Sorensen B. Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. Blood Coagul Fibrinolysis 2009;20:358-65.
19. D'Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, Vigano D'Angelo S. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002;87:1074-80.
20. Jonsson M, Hillarp A, Svensson P. Comparison between CoaguChek S-and Owren-type prothrombin time assay for moni toring anticoagulant therapy. Thromb Res 2004;114:83-9.
21. van den Besselaar AM. Precision and accuracy of the international normalized ratio in oral anticoagulant control. Haemostasis 1996;26(Suppl 4):248-65.
22. Watson C, Kitchen S, Woolley AM, Young L, Malia RG. Recombinant and tissue extract thromboplastins for determination of international normalised ratio in over-anticoagulated patients. Br J Biomed Sci 1999;56:123-7.
23. Solvik UO, Petersen PH, Monsen G, Stavelin AV, Sandberg S. Discrepancies in international normalized ratio results between instruments: a model to split the variation into subcomponents. Clin Chem 2010;56:1618-26.
24. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995;346:1085-7.
25. Sokal RR, Rolph FJ. Assumption of analysis of variance. In: Biometry, 3rd ed. New York: W. H. Freeman and Company, 1995:392-450.
26. Burdick RK, Graybill FA. Confidence intervals on variance components. In: Statistics: textbooks and monographs, vol 127. New York: Marcel Dekker, 1992.
27. Burnett RW. Accurate estimation of standard deviations for quantitative methods used in clinical chemistry. Clin Chem 1975;21:1935-8.
28. Shermock KM, Streiff MB, Pinto BL, Kraus P, Pronovost PJ. Novel analysis of clinically relevant diagnostic errors in pointof-care devices. J Thromb Haemost 2011;9:1769-75.
29. Smith SA, Comp PC, Morrissey JH. Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost 2006;4:820-7.
30. Quick AJ. The prothrombin in hemophilia and obstructive jaundice. J Biol Chem 1935;109:73-84.
31. Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959;2:754-8.
32. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989;62:788-91.
33. Moore G, Henley A, Cotton S, Tugnait S, Rangarajan S. Clinically significant differences between point-of-care analysers and a standard analyser for monitoring the international norma lized ratio in oral anticoagulant therapy: a multiinstrument evaluation in a hospital outpatient setting. Blood Coagul Fibrinolysis 2007;18:287-92.
34. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-93.
35. Andrews D, Low P. Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
36. WHO expert committee on biological standardization. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. WHO technical report series 1999;889:64-93.